Aquestive Therapeutics (AQST) Amortization of Deferred Charges (2017 - 2026)

Aquestive Therapeutics' Amortization of Deferred Charges history runs 10 years deep, the most recent figure standing at $60000.0 for Q1 2026.

• In Q1 2026, Amortization of Deferred Charges fell 97.82% year-over-year to $60000.0; the TTM figure through Mar 2026 stood at -$2.4 million (down 881.79% YoY), while the FY2025 annual figure was $243000.0, up 2.97% from the prior year.
• Amortization of Deferred Charges was $60000.0 for Q1 2026 at Aquestive Therapeutics, down from $62000.0 in the prior quarter.
• In the past five years, Amortization of Deferred Charges ranged from a high of $2.8 million in Q1 2025 to a low of -$7.8 million in Q4 2024.
• Historically, Amortization of Deferred Charges has averaged $147411.8 across 5 years, with a median of $58000.0 in 2022.
• Biggest YoY gain for Amortization of Deferred Charges was 89000.0% in 2024; the steepest drop was 532.65% in 2024.
• A 5-year view of Amortization of Deferred Charges shows it stood at $58000.0 in 2022, then soared by 3000.0% to $1.8 million in 2023, then plunged by 532.65% to -$7.8 million in 2024, then surged by 100.8% to $62000.0 in 2025, then declined by 3.23% to $60000.0 in 2026.
• The last three Amortization of Deferred Charges figures came in at $60000.0 (Q1 2026), $62000.0 (Q4 2025), and -$5.3 million (Q3 2025), per Business Quant data.